CRY - CryoLife, Inc.
CryoLife, Inc.
1655 Roberts Boulevard NW
Kennesaw, GA 30144
United States
770-419-3355
http://www.cryolife.com
Sector: Healthcare
Industry: Medical Devices
Full-time employees: 1,100
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. James Patrick MacKin | Chairman, Pres & CEO | 1.33M | 3.3M | 1967 |
| Mr. David Ashley Lee CPA, CPA | Exec. VP, COO & CFO | 711.69k | 437.78k | 1965 |
| Ms. Jean F. Holloway | Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. | 551.93k | 154.59k | 1957 |
| Mr. John E. Davis | Sr. VP of Global Sales & Marketing | 523.38k | 571.33k | 1965 |
| Ms. Amy D. Horton CPA, CPA | VP & Chief Accounting Officer | N/A | N/A | 1970 |
Description
CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser consoles, related service and maintenance, and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina. In addition, it distributes E-vita OPEN PLUS, a hybrid stent graft system for the surgical and endovascular treatment; E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; E-vita THORACIC 3G, a stent graft system for the endovascular treatment of thoracic aortic aneurysms; and E-tegra, an abdominal aortic aneurysms stent graft system for the endovascular treatment. Further, the company offers vascular preservation services; and synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures. The company serves physicians, hospitals, and other healthcare industries, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
Corporate governance
CryoLife, Inc.’s ISS governance QualityScore as of 4 October 2019 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 3; Compensation: 3.